New research from Karolinska Institutet shows that the blood test Stockholm3 together with magnetic resonance imaging and targeted prostate biopsies may lead to a significant decrease in the number of biopsy procedures and diagnoses of harmless disease.
The study compares traditional detection of prostate cancer with a novel practice using a blood test, the Stockholm3 test, in combination with magnetic resonance imaging (MRI) and targeted prostate biopsies.
More men get a correct diagnosis and treatment
The results show that the suggested diagnostic strategy decreased the number of biopsy procedures with 38% and the number of men getting a diagnose with the harmless disease by 42%.
At the same time, the number of men diagnosed with potentially harmful cancer increased with 10%. The study was performed in collaboration with Swedish (Stockholm) and Norwegian (Oslo, Tönsberg) urology practices and includes 532 men.
"We show that a combination of the Stockholm3 test and targeted prostate biopsies might increase the number of men with a potentially dangerous disease that gets a diagnosis," said Tobias Nordström, a researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet and urologist at Danderyd Hospital.
"At the same time, we can spare many men from unnecessary prostate biopsies. This means that more men get a correct diagnosis and treatment and that we can decrease unnecessary discomfort and risks," said Nordström.
Need for improved diagnosis
In the European Union, prostate cancer is the most frequently diagnosed cancer among men, with around 365,000 new cases yearly and 77,000 men dying from prostate cancer. Current practice includes a so-called PSA test and systematic prostate biopsies where 10-12 samples are taken from the prostate.
The PSA test has been controversial because it only poorly differentiates between lethal and harmless prostate cancer. The Stockholm3 test is an alternative test method that combines five biomarkers, over 100 genetic markers and clinical data such as age, previous biopsies and family history of prostate cancer to better assess the risk of potentially harmful prostate cancer.
"The current study confirms our previous findings showing the value of the Stockholm3 test as part of the diagnosis of prostate cancer. Studies of this type have been requested by the National Board of Health and Welfare in Sweden," said Tobias Nordström.
The Swedish Cancer Society funded the research, the Swedish Research Council, the Swedish Research Council for Health, Working Life and Welfare, The Strategic Research Programme in Cancer at Karolinska Institute (StratCan), Karolinska Institutet och The Swedish e-Science Research Centre (SeRC).
The Stockholm3 test was developed by researchers at Karolinska Institutet in collaboration with Thermo Fisher Scientific. Professor Henrik Grönberg, a lead author of this study, has patent applications for the Stockholm3 test licensed to Thermo Fisher Scientific and might receive royalties from sales related to these patents. Co-author Martin Eklund is named on some of these patent applications.